Higgins G A, Conn J H, Jordan P H, Humphrey E W, Roswit B, Keehn R J
Ann Surg. 1975 May;181(5):624-31. doi: 10.1097/00000658-197505000-00017.
In a prospective randomized trial, 700 patients with a confirmed histological diagnosis of adenocarcinoma of the rectum or rectosigmoid were randomized to receive radiotherapy prior to operation (2000 to 2500 rads in two weeks) or surgery alone. Five year observed survival in the 453 patients on whom "curative" resection was possible was 48.5% in the X-ray treated group compared with 38.8% in controls, while in the 305 having low lying lesions requiring abdominoperineal resection, survival in the treated group was 46.9% compared with 34.3% in controls. Although suggestive of a treatment benefit, neither is considered statistically significant. Histologically positive lymph nodes were found in 41.2% of the control group and in only 27.8% of the patients receiving radiotherapy. Reveiw of all patients who died during the study shows a consistently lower death rate from cancer in the radiotherapy group. Although this study suggests a treatment benefit from preoperative radiotherapy, further studies now in progress by this group and others are necessary to determine the optimal dose regimen.
在一项前瞻性随机试验中,700例经组织学确诊为直肠或直肠乙状结肠腺癌的患者被随机分为两组,一组在手术前接受放疗(两周内给予2000至2500拉德),另一组仅接受手术。在453例可行“根治性”切除的患者中,接受X线治疗组的5年观察生存率为48.5%,而对照组为38.8%;在305例低位病变需行腹会阴联合切除术的患者中,治疗组的生存率为46.9%,对照组为34.3%。虽然提示有治疗益处,但两者均无统计学意义。对照组中41.2%的患者组织学检查发现淋巴结阳性,而接受放疗的患者中这一比例仅为27.8%。对研究期间所有死亡患者的回顾显示,放疗组的癌症死亡率始终较低。虽然这项研究提示术前放疗有治疗益处,但该研究小组和其他机构目前正在进行的进一步研究对于确定最佳剂量方案是必要的。